ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2459

Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis

Fernanda Genre1, Raquel López-Mejías1, Mercedes García-Bermúdez2, Santos Castañeda3, Carlos González-Juanatey4, Javier Llorca5, Alfonso Corrales1, Begoña Ubilla1, Jose A. Miranda-Filloy6, Encarnación Amigo6, Trinitario Pina Murcia1, Carmen Gómez-Vaquero7, Luis Rodriguez-Rodriguez8, Benjamin Fernández Gutierrez8, Alejandro Balsa9, Dora Pascual-Salcedo9, Francisco Javier López-Longo10, Patricia Carreira11, Ricardo Blanco12, Isidoro González-Alvaro13, Javier Martin14 and Miguel A González-Gay1, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, 4Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, 5Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 6Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, 7Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, 8Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, 9Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, 10Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, 11Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, 12Hospital Marques de Valdecilla, Santander, Spain, 13Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 14Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, osteoprotegerin, polymorphism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an increased risk of atherosclerotic disease in the general population. Several polymorphisms in the OPG gene with functional effects on cardiovascular disease in non-rheumatic individuals have been described. Therefore, we aimed to analyze the effect of three of these functional OPG polymorphisms on the risk of cardiovascular disease in a large and well-characterized cohort of Spanish patients with rheumatoid arthritis.

Methods: Three OPG gene variants (rs3134063, rs2073618 and rs3134069) were genotyped by TaqMan assays in 2,027 Spanish patients with rheumatoid arthritis. All the patients fulfilled the 1987 American College of Rheumatology (ACR) and also the 2010 classification criteria for RA. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing was positive in 997 out of the 1,714 tested. Also, 18.3% of the whole series had experienced cardiovascular events, including 5.4% with cerebrovascular accidents. The relationship between OPG variants and cardiovascular events was assessed using Cox regression.

Results: No association between OPG gene variants and cardiovascular disease was observed in the whole group of rheumatoid arthritis patients or in anti-CCP positive patients. Nevertheless, a protective effect of CGA haplotype on the risk of cardiovascular disease in general, and specifically in the risk of cerebrovascular complications after adjusting for sex, age at disease diagnosis and traditional cardiovascular risk factors was disclosed in anti-CCP negative patients (HR=0.54; 95%CI: 0.31-0.95; p=0.032 and HR=0.17; 95%CI: 0.04-0.78; p=0.022, respectively). These results were in accordance with a reduced risk of developing cerebrovascular complications observed in those anti-CCP negative patients who carried the OPG rs2073618 GG genotype after adjusting for potential confounder factors (HR=0.17; 95% CI: 0.03-0.89; p=0.035).

Conclusion: Our results indicate a protective effect of the OPG CGA haplotype on cardiovascular risk, mainly due to a protective effect against cerebrovascular events in anti-CCP negative rheumatoid arthritis patients.

This study was supported by European Union FEDER funds and “Fondo de Investigación Sanitaria” (grants PI06/0024, PS09/00748 and PI12/00060) (Spain). This work was also partially supported by RETICS Programs RD12/0009 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain), and in part by grants from the European IMI BTCure Program. FG and BU are supported by funds from the RETICS Program (RIER) (RD12/0009/0013). RLM is a recipient of a Sara Borrell postdoctoral fellowship from the “Instituto de Salud Carlos III” at the Spanish Ministry of Health (Spain) (CD12/00425).


Disclosure:

F. Genre,
None;

R. López-Mejías,
None;

M. García-Bermúdez,
None;

S. Castañeda,
None;

C. González-Juanatey,
None;

J. Llorca,
None;

A. Corrales,
None;

B. Ubilla,
None;

J. A. Miranda-Filloy,
None;

E. Amigo,
None;

T. Pina Murcia,
None;

C. Gómez-Vaquero,
None;

L. Rodriguez-Rodriguez,
None;

B. Fernández Gutierrez,
None;

A. Balsa,
None;

D. Pascual-Salcedo,
None;

F. J. López-Longo,
None;

P. Carreira,
None;

R. Blanco,
None;

I. González-Alvaro,
None;

J. Martin,
None;

M. A. González-Gay,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoprotegerin-cga-haplotype-protection-against-cerebrovascular-complications-in-anti-ccp-negative-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology